Home > News Center
 
Contact Us
Shanghai BravoBio Co., Ltd.
Add:Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
 
CFDA issues announcement on the implementation of the newly revised GMP for sterile pharmaceutical products
Jan. 18, 2014
 
On December 31, 2013, China Food and Drug Administration (CFDA) issued an announcement on the implementation of the Good Manufacturing Practice for Drugs (2010 Revision) for sterile pharmaceutical products. According to the implementation plan of Good Manufacturing Practice for Drugs (2010 Revision) (hereinafter referred to as the newly revised GMP), the production of blood products, vaccines, injections and other sterile pharmaceutical products should meet the requirements of the newly revised GMP before December 31, 2013.
 
US President's Cancer Panel supports Merck's and GSK's HPV vaccines
Feb. 13, 2014
 
The President's Cancer Panel has stepped in to promote Merck's and GSK's HPV vaccines to prevent cancer. The panel wants to have CDC develop communication strategies for physicians and use electronic systems to track vaccinations. The panel also proposes changing federal laws and regulations to ensure Medicaid reimbursement for HPV vaccines.
 
The State Council passes the draft amendment to the Regulations for the Supervision and Administration of Medical Devices
Feb. 18, 2014
 
The draft amendment to the Regulations for the Supervision and Administration of Medical Devices was adopted at the executive meeting of the State Council on February 12, 2014, and will be promulgated and implemented soon.
 
Indian government negotiates with Merck and GSK to bring down HPV vaccine price
Feb 19, 2014
 
Indian central government is negotiating with GSK and Merck to bring down the price of HPV vaccine each dose from $130 to $4.50 in India, making the vaccine more affordable in India. HPV serotypes 16 and 18 account for nearly 70 per cent of cervical cancer in India.
 
WHO succeeded in transporting vaccines without cold chain
Feb. 20, 2014
 
WHO, together with PATH, trialed the distribution model of Meningitis A vaccine MenAfriVac outside of the cold chain for up to four days in a 10-day vaccination drive in Benin in 2012. Although the ambient temperatures reached almost 39℃, no vaccines were discarded because of heat exposure. Free from the need of cold chain, vaccines will be more accessible and economical.
 
Sanofi supplies inactive polio vax to GAVI and GPEI for $1 a dose
March 6, 2014
 
Sinofi signed a deal with GAVI and the Global Polio Eradication Initiative (GPEI) to supply the inactive polio vaccine (IPV) to GAVI-supported countries for as low as $1 per dose. More than 120 countries will benefit from this tender to introduce at least 1 dose of IPV into the routine immunization schedules, the price being $1 a shot in 73 low-income counties and $2.04-$2.38 a shot in middle-income countries beginning in July.
 
Merck's Gardasil reduces about 50% risk of developing cervical cancer
March 8, 2014
 
By looking at the health records of 100,000 young women in Merck HPV vaccination catch-up program in Australia, researchers found out women who had received three doses were 46% less likely to develop high-grade cervical abnormalities. The vaccine also offered 34% protection against other cervical abnormalities. The study suggests these young women are better protected than their peers who received two or fewer doses.
 
U.K. considering a 2-dose HPV vaccination
March 13, 2014
 
UK is considering switching to a two-dose vaccination model forhuaman papillomavirus (HPV) immunization. The Merck-Sanofi joint venture which is selling Gadasil in UK had just cleared the first European regulatory hurdle last month. If the two-shot model is approved, UK may use the money saved to vaccinate boys against HPV.
 
BravoBio attended Biopharma Asia 2014 in Singapore
Mar. 16, 2014
 
The President of BravoBio, Dr. Ke Wu was invited as chairman in the conference held in Suntec Convention & Exhibition Center, Singapore on Mar 12. The topic-- Biotech entrepreneurship: Examining the rise of Asia's top biotech companies & start-ups attracted more than 100 C- level audiences. On Mar.11, he also showed the history and performances of the company in the theater of the conference as per organizer's request.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next